분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2015-01-07 01:00:59 , Hit : 1304
 CVS Gives Preferred Status to Gilead’s Hepatitis C Drugs

AbbVie’s Viekira Pak Will be Available If a Patient Receives Medical Exception or Prior Authorization


AbbVie’s Viekira Pak isn’t included on CVS Health’s drug formulary.  Bloomberg News  
.

By
Joseph Walker









Updated Jan. 5, 2015 12:27 p.m. ET  


The battle for supremacy in one of the fastest-growing pharmaceutical markets intensified on Monday, with  CVS Health  Corp. saying it will make  Gilead Sciences  Inc. ’s drugs Sovaldi and Harvoni the exclusive options for patients with hepatitis C.

A competing treatment made by  AbbVie  Inc., called Viekira Pak, will be excluded from CVS’s drug formulary of approved medications, except in cases when it is medically necessary, CVS said in a letter sent to employment-benefit consultants that was reviewed by The Wall Street Journal.

The letter from CVS, a retail chain and pharmacy-benefits manager, doesn’t indicate whether Gilead gave CVS a discount on the expensive hepatitis C drugs. Sovaldi costs $84,000 per patient and Harvoni $94,500 per patient in the U.S. for 12-week treatments. Gilead and CVS declined to comment on specifics of the deal.

“Our goal was to create the lowest net-cost solution for the entire population of patients with all genotypes of hepatitis C,” Christine K. Cramer, a CVS spokeswoman, said in an email. CVS made its decision based on a clinical review of the different hepatitis C regimens and their costs, she said.




AbbVie’s Viekira Pak costs $83,319 per patient in the U.S. for a 12-week regimen.


World-wide sales of new hepatitis C drugs, which have higher cure rates and fewer side effects than older therapies for the viral liver disease, are estimated to have reached $13 billion in 2014, according to RBC Capital Markets. The hepatitis C drug market is expected to grow 42% to $18.5 billion this year, RBC said.

Doctors and patients have praised the drugs’ cure rates, but insurers and state health officials have criticized their pricing, calling it unsustainable. Many state Medicaid programs have limited access to the drugs because of the cost.

Express Scripts Holding  Co. , the largest U.S. pharmacy benefit manager, said in December it had agreed to give preferred formulary status to AbbVie’s Viekira Pak in exchange for a discount from AbbVie. Express Scripts, which has been among the most vocal critics of Gilead’s pricing of hepatitis C drugs, said it would exclude from its formularies Gilead’s drugs for hepatitis C patients with the most common form of the disease, known as genotype 1. Express Scripts also said it would make AbbVie’s drug available to all patients, regardless of their disease severity.

Gilead shares fell 13% through the end of December after the agreement between Express Scripts and AbbVie was announced, with some investors worried AbbVie would use price discounting to gain a larger share of the hepatitis C drug market than anticipated. The Nasdaq Biotechnology Index fell 4.1% over the same period as some analysts worried of increased pressure from pharmacy-benefit managers and health insurers on drug pricing.

On Monday, shares of Gilead were up 2% to $96.79. AbbVie shares fell 1.9% to $64.65.



Further reading

Docs Divided Over Discount on AbbVie Drug
The Hepatitis C Price Wars Begin
AbbVie Pins Hopes on Hepatitis C Treatment
.
CVS’s policy will go into effect Jan. 7 and will apply to all hepatitis C genotypes. The company’s policy will apply to Medicare and Medicaid patients who receive drug benefits through CVS, as well as beneficiaries covered under health plans sold through marketplace exchanges and CVS’s standard commercial formulary. The change won’t necessarily apply to CVS customers who use custom formularies, the CVS letter said.

Sales of Gilead’s Sovaldi, approved in late 2013, were $8.55 billion in the first three quarters of 2014 in what is thought to be the most successful drug launch ever. Harvoni was approved by the Food and Drug Administration this past October as the first treatment for genotype 1 cases of hepatitis C that doesn’t require two older drugs known to cause serious side effects.

AbbVie received approval for its Viekira Pak on Dec. 19.

“Gilead is very pleased to have reached an agreement with CVS that will enable access to Harvoni for people living with HCV,” Amy Flood, a Gilead spokeswoman, said in an email.

Viekira Pak is thought to be as effective as Gilead’s drugs in genotype 1 patients, though not as convenient because it requires patients to take more pills at one time.

“Our multiyear agreement with Express Scripts is an example of how we will ensure all hepatitis C patients beyond just the very sickest…gain access to treatment,” David Freundel, an AbbVie spokesman, said in an email.

“We welcome others to follow our lead,” Brian Henry, an Express Scripts spokesman, said of CVS’s agreement with Gilead.

—Peter Loftus contributed to this article.

Write to Joseph Walker at joseph.walker@wsj.com







1007   US pharmacy deals could cut costs of AbbVie and Gilead's HCV treatments  이성욱 2015/01/08 1665
1006   Janssen, Isis Pharma Ink Up-to-$835M Antisense Agreement  이성욱 2015/01/07 1181
  CVS Gives Preferred Status to Gilead’s Hepatitis C Drugs  이성욱 2015/01/07 1304
1004   Mass. developer of messenger RNA drugs gets $450M funding boost  이성욱 2015/01/07 966
1003   아직도 풀리지 않은 STAP줄기세포 미스터리  이성욱 2015/01/06 1009
1002   에볼라 확산원인에 대한 새로운 주장  이성욱 2015/01/06 1114
1001   Scientists explain how stem cells and 'bad luck' cause cancer  이성욱 2015/01/06 926
1000   자가 항체에 의한 전신 홍반성 루프스 발생 기작  이성욱 2015/01/05 1552
999   줄기세포로 만든 초기 난자와 정자  이성욱 2014/12/31 1148
998   텔로머레이즈 기반 유전자 요법으로 심장마비 치료  이성욱 2014/12/24 1664
997   일본의 검증팀 STAP 세포 재현 포기, 오보카타 사임  이성욱 2014/12/23 1075
996   아수라장 속에서 탄생한 생명  이성욱 2014/12/17 1237
995   암 생존율을 높일 수 있는 면역세포  이성욱 2014/12/16 1091
994   FDA approves 9-valent HPV vaccine for certain cancers  이성욱 2014/12/12 1142
993   C형 간염 치료에서 비용 효율성을 보인 시메프레비르(simeprevir) 기반 요법  이성욱 2014/12/11 1714
992   Y 염색체 상실을 초래할 수 있는 흡연  이성욱 2014/12/10 1341
991   술의 역사: 영장류가 진화한 것은 알코올 섭취능력 때문?  이성욱 2014/12/04 1267
990   혈우병 환자들에게 안전성과 효과를 입증한 유전자 요법  이성욱 2014/11/27 1616
989   EMA panel recommends approval of DAA regimen for patients with HCV  이성욱 2014/11/26 1284
988   AMD를 치료하는데 사용될 수 있는 HIV/AIDS 약물들  이성욱 2014/11/26 1393

[이전 10개] [1]..[11][12][13] 14 [15][16][17][18][19][20]..[64] [다음 10개]
 

Copyright 1999-2021 Zeroboard / skin by ROBIN